dm+d

Unassigned

New Medicines

LupuzorSystemic lupus erythematosus (SLE)

Information

Lupuzor
New molecular entity
ImmuPharma
Avion

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

T cell inhibitor
SLE affects about 5 in 10,000 people in the UK. It is ten times more common in women than men and more common in people from Afro-Caribbean, Asian or Chinese origin. It typically develops between ages 20 and 40 years. Only 3 in 100 children will inherit SLE from affected patients.
Systemic lupus erythematosus (SLE)
Subcutaneous